# Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

> **NCT02612311** · PHASE3 · TERMINATED · sponsor: **TG Therapeutics, Inc.** · enrollment: 603 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Obinutuzumab
- **BIOLOGICAL:** Ublituximab
- **DRUG:** TGR-1202
- **DRUG:** Chlorambucil

## Key facts

- **NCT ID:** NCT02612311
- **Lead sponsor:** TG Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-19
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 603 (ACTUAL)
- **Why stopped:** Strategic/Business decision
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612311, "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02612311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*